M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial
Yoichiro Hirakawa,Hisatomi Arima,Sophia Zoungas,Sophia Zoungas,Toshiharu Ninomiya,Mark E. Cooper,Pavel Hamet,Giuseppe Mancia,Neil R Poulter,Stephen B. Harrap,Mark Woodward,John Chalmers +11 more
TL;DR: Consistency of glycemic control is important to reduce the risks of vascular events and death in type 2 diabetes.
Journal ArticleDOI
Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat
Chris Tikellis,Peter J. Wookey,Riccardo Candido,Sofianos Andrikopoulos,Sofianos Andrikopoulos,Merlin C. Thomas,Mark E. Cooper +6 more
TL;DR: Improvements in structural parameters were also associated with functional improvements in first-phase insulin secretion and provide a possible mechanism for the reduced incidence of new-onset diabetes that has been observed in clinical trials of RAS blockade.
Journal ArticleDOI
Mechanisms of diabetic vasculopathy : An overview
TL;DR: It is likely that the effects of inhibitors of this pathway such as aminoguanidine on cytokine production may play a pivotal role in mediating the renal, retinal, and vasoprotective effects observed with this agent in experimental diabetes.
Journal ArticleDOI
Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: An international comparison
John A. McKnight,Sarah H. Wild,Maxine Lamb,Mark E. Cooper,Mark E. Cooper,Timothy W. Jones,Timothy W. Jones,Elizabeth A. Davis,Elizabeth A. Davis,Sabine E. Hofer,Maria Fritsch,Edith Schober,Jannet Svensson,Thomas Almdal,Robert I. M. Young,Justin T. Warner,Justin T. Warner,B. Delemer,P.F. Souchon,Reinhard W. Holl,Wolfram Karges,D.M. Kieninger,Stelios Tigas,Alexandra Bargiota,C. Sampanis,Valentino Cherubini,Rosaria Gesuita,Ieva Strele,Santa Pildava,Kirsten J Coppell,Gregory A. Magee,J.G. Cooper,Sean F. Dinneen,Katarina Eeg-Olofsson,Ann-Marie Svensson,S Gudbjornsdottir,H. J. Veeze,Henk-Jan Aanstoot,Mykola Khalangot,William V. Tamborlane,Kellee M. Miller +40 more
TL;DR: The aim was to compare glycaemic control among people with Type 1 diabetes using data gathered in regional or national registries to reduce complications.
Journal ArticleDOI
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes
Josephine M. Forbes,Vicki Thallas,Merlin C. Thomas,Hank W. Founds,Wendy C. Burns,George Jerums,Mark E. Cooper +6 more
TL;DR: The utility of a cross‐link breaker as a treatment for diabetic nephropathy is demonstrated and effects not only on renal AGEs but on putative mediators of renal injury, such as prosclerotic cytokines and oxidative stress are described.